Last reviewed · How we verify

Triptorelin (I.N.N.) — Competitive Intelligence Brief

Triptorelin (I.N.N.) (Triptorelin (I.N.N.)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH agonist. Area: Oncology; Endocrinology.

phase 3 GnRH agonist GnRH receptor (GNRHR) Oncology; Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Triptorelin (I.N.N.) (Triptorelin (I.N.N.)) — Ipsen. Triptorelin is a GnRH agonist that stimulates the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, initially increasing sex hormone levels before causing sustained suppression through receptor desensitization.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Triptorelin (I.N.N.) TARGET Triptorelin (I.N.N.) Ipsen phase 3 GnRH agonist GnRH receptor (GNRHR)
triptorelin, recombinant LH triptorelin, recombinant LH IVI Madrid marketed GnRH agonist with recombinant LH supplementation GnRH receptor; LH receptor
Agonist GnRH; estradiol Valerate; progesterone Agonist GnRH; estradiol Valerate; progesterone Instituto Valenciano de Infertilidad, IVI VALENCIA marketed Hormone combination therapy; GnRH agonist with steroid hormones GnRH receptor; estrogen receptor; progesterone receptor
Ultra-Long GnRH Agonists + Letrozole Ultra-Long GnRH Agonists + Letrozole University of Palermo marketed GnRH agonist + aromatase inhibitor combination GnRH receptor; aromatase (CYP19A1)
TRIPTORELIN ACETATE, hCG TRIPTORELIN ACETATE, hCG HaEmek Medical Center, Israel marketed GnRH agonist GnRH receptor
Gonapeptyl® Gonapeptyl® University Hospital, Ghent marketed GnRH agonist GnRH receptor
Leuprolide (GnRH agonists) Leuprolide (GnRH agonists) University of Pisa marketed GnRH agonist GnRH receptor (GNRHR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GnRH agonist class)

  1. Takeda · 4 drugs in this class
  2. Abbott · 3 drugs in this class
  3. Ipsen · 3 drugs in this class
  4. Changchun GeneScience Pharmaceutical Co., Ltd. · 3 drugs in this class
  5. University of Pisa · 2 drugs in this class
  6. Chong Qing Reproducive and Genetic Institute · 1 drug in this class
  7. Chesapeake Urology Research Associates · 1 drug in this class
  8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  9. Enteris BioPharma Inc. · 1 drug in this class
  10. Colorado Center for Reproductive Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Triptorelin (I.N.N.) — Competitive Intelligence Brief. https://druglandscape.com/ci/triptorelin-i-n-n. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: